Patients with grade 3 glioma exhibiting a low frequency of CD3−/CD56+ NK cells had a median OS of 60 months, whereas patients with a high frequency of CD3−/CD56+ NK cells had a median OS of 88 months (Figure 8A, p > 0.05). This evidence concerns the gene NCAM1 and glioma.